

Factors Influencing the CNS Distribution of a Novel PI3K/mTOR Inhibitor GSK2126458: Implications for Overcoming Resistance with Combination Therapy for Melanoma Brain Metastases

Authors: Shruthi Vaidhyathan*, Brynna Wilken-Resman*, Daniel J Ma, Karen E Parrish, Rajendar K Mittapalli , Brett L Carlson, Jann N Sarkaria, William F Elmquist

Journal of Pharmacology and Experimental Therapeutics

Supplemental Figure 1




Figure Legend

Plasma and brain concentrations after a 48 hour simultaneous intraperitoneal infusion of GSK2126458 (1 µg/hr) dabrafenib (2.5 µg/hr) and trametinib (0.5 µg/hr), n=3-4, plasma concentrations are not significantly different as compared to corresponding wild-type, *p< 0.05 compared to corresponding brain concentration in wild-type.**